DE3107100A1 - Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung - Google Patents

Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung

Info

Publication number
DE3107100A1
DE3107100A1 DE19813107100 DE3107100A DE3107100A1 DE 3107100 A1 DE3107100 A1 DE 3107100A1 DE 19813107100 DE19813107100 DE 19813107100 DE 3107100 A DE3107100 A DE 3107100A DE 3107100 A1 DE3107100 A1 DE 3107100A1
Authority
DE
Germany
Prior art keywords
solution
alkyl
acid
hydrogen
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19813107100
Other languages
German (de)
English (en)
Inventor
Jorge Dr. Casals-Stenzel
Ekkehard Dr. Schillinger
Norbert Dr. Schwarz
Werner Dr. Skuballa
Michael Harold Dr. 1000 Berlin Town
Helmut Prof. Dr. Vorbrüggen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to DE19813107100 priority Critical patent/DE3107100A1/de
Priority to AU80388/82A priority patent/AU8038882A/en
Priority to JP57023695A priority patent/JPS57176960A/ja
Priority to CS821172A priority patent/CS228916B2/cs
Priority to ES509738A priority patent/ES8301914A1/es
Priority to AT82730015T priority patent/ATE36152T1/de
Priority to DK72782A priority patent/DK72782A/da
Priority to CA000396656A priority patent/CA1205468A/en
Priority to EP82730015A priority patent/EP0059158B1/de
Priority to DE8282730015T priority patent/DE3278854D1/de
Priority to HU82519A priority patent/HU187649B/hu
Priority to IL65055A priority patent/IL65055A0/xx
Priority to IE355/82A priority patent/IE54097B1/en
Priority to US06/350,674 priority patent/US4446147A/en
Publication of DE3107100A1 publication Critical patent/DE3107100A1/de
Priority to US06/591,719 priority patent/US4567195A/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03Monocarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/26Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4015Esters of acyclic unsaturated acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40Esters thereof
    • C07F9/4003Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4018Esters of cycloaliphatic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE19813107100 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung Ceased DE3107100A1 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE19813107100 DE3107100A1 (de) 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
AU80388/82A AU8038882A (en) 1981-02-20 1982-02-11 Azaprostacyclins
JP57023695A JPS57176960A (en) 1981-02-20 1982-02-18 Azaprostacycline, manufacture and medicine containing same
CA000396656A CA1205468A (en) 1981-02-20 1982-02-19 Azaprostacyclins, process for their manufacture and their pharmaceutical use
HU82519A HU187649B (en) 1981-02-20 1982-02-19 Process for preparing azaprostacyclin derivatives and pharmaceutical compositions containing such compounds as active substances
AT82730015T ATE36152T1 (de) 1981-02-20 1982-02-19 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
DK72782A DK72782A (da) 1981-02-20 1982-02-19 Azaprostacykliner,fremgangsmaade til deres fremstilling og deres fremstilling og deres farmaceutiske anvendelse
CS821172A CS228916B2 (en) 1981-02-20 1982-02-19 Method of preparing new derivatives of 9 alpha,6-nitril
EP82730015A EP0059158B1 (de) 1981-02-20 1982-02-19 Azaprostacycline, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
DE8282730015T DE3278854D1 (en) 1981-02-20 1982-02-19 Aza prostacyclins, their preparation and therapeutic applications
ES509738A ES8301914A1 (es) 1981-02-20 1982-02-19 "procedimiento para la preparacion de azaprostaciclinas".
IL65055A IL65055A0 (en) 1981-02-20 1982-02-19 Azaprostacyclins,process for their manufacture and pharmaceutical preparations containing them
IE355/82A IE54097B1 (en) 1981-02-20 1982-02-22 Azaprostacyclins, process for their manufacture and their pharmaceutical use
US06/350,674 US4446147A (en) 1981-02-20 1982-02-22 Azaprostacyclins, their preparation and pharmaceutical use
US06/591,719 US4567195A (en) 1981-02-20 1984-03-21 Azaprostacyclins, their preparation and pharmaceutical use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813107100 DE3107100A1 (de) 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung

Publications (1)

Publication Number Publication Date
DE3107100A1 true DE3107100A1 (de) 1982-09-09

Family

ID=6125738

Family Applications (2)

Application Number Title Priority Date Filing Date
DE19813107100 Ceased DE3107100A1 (de) 1981-02-20 1981-02-20 Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE8282730015T Expired DE3278854D1 (en) 1981-02-20 1982-02-19 Aza prostacyclins, their preparation and therapeutic applications

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE8282730015T Expired DE3278854D1 (en) 1981-02-20 1982-02-19 Aza prostacyclins, their preparation and therapeutic applications

Country Status (13)

Country Link
US (2) US4446147A (https=)
EP (1) EP0059158B1 (https=)
JP (1) JPS57176960A (https=)
AT (1) ATE36152T1 (https=)
AU (1) AU8038882A (https=)
CA (1) CA1205468A (https=)
CS (1) CS228916B2 (https=)
DE (2) DE3107100A1 (https=)
DK (1) DK72782A (https=)
ES (1) ES8301914A1 (https=)
HU (1) HU187649B (https=)
IE (1) IE54097B1 (https=)
IL (1) IL65055A0 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1246560A (en) * 1984-10-09 1988-12-13 Gary F. Cooper Intermediates for making 16-phenoxy and 16- substituted phenoxy-prostatrienoic acid derivatives
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
SK9502003A3 (en) * 2001-01-26 2003-12-02 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
WO2002058733A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
IL156445A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
PT1385548E (pt) * 2001-01-26 2007-08-24 Schering Corp Combinações de um inibidor ou de inibidores de absorção de esteróis com agente (s) para o tratamento de doenças vasculares
AR035533A1 (es) * 2001-01-26 2004-06-02 Schering Corp Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
WO2002058685A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
ES2275007T3 (es) * 2001-05-25 2007-06-01 Schering Corporation Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer.
HUP0401501A3 (en) * 2001-09-21 2012-02-28 Schering Corp Treating or preventing vascular inflammation using pharmaceutical compositions containing sterol absorption inhibitor(s)
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) * 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
US7459442B2 (en) * 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1601668B1 (en) * 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
CA2517572C (en) 2003-03-07 2011-12-13 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2007510659A (ja) * 2003-11-05 2007-04-26 シェーリング コーポレイション 脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
EP2527360B1 (en) 2007-06-04 2015-10-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2826096A1 (de) * 1977-06-17 1979-01-04 Upjohn Co Prostaglandinanaloga
DE2907118A1 (de) * 1979-02-20 1980-09-04 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2734791A1 (de) * 1977-07-29 1979-02-15 Schering Ag Neue prostaglandin-i tief 2 -derivate und verfahren zu ihrer herstellung
US4211706A (en) * 1978-10-13 1980-07-08 The Upjohn Company 9-Deoxy-9α,6-nitrilo or 6,9α-imino-17,18-didehydro-PGF compounds
DE2902809A1 (de) * 1979-01-25 1980-08-07 Hoechst Ag Neue analoga von prostacyclin
US4496742A (en) * 1981-10-13 1985-01-29 The Upjohn Company Analogs of 5,6-dihydro PGI2

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2826096A1 (de) * 1977-06-17 1979-01-04 Upjohn Co Prostaglandinanaloga
DE2907118A1 (de) * 1979-02-20 1980-09-04 Schering Ag Neue prostacyclin-derivate und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
CA1205468A (en) 1986-06-03
CS228916B2 (en) 1984-05-14
US4567195A (en) 1986-01-28
EP0059158B1 (de) 1988-08-03
AU8038882A (en) 1982-08-26
ES509738A0 (es) 1983-02-01
HU187649B (en) 1986-02-28
DK72782A (da) 1982-08-21
JPH0245622B2 (https=) 1990-10-11
IE820355L (en) 1982-08-20
EP0059158A3 (en) 1983-03-09
ATE36152T1 (de) 1988-08-15
EP0059158A2 (de) 1982-09-01
IL65055A0 (en) 1982-04-30
IE54097B1 (en) 1989-06-21
US4446147A (en) 1984-05-01
ES8301914A1 (es) 1983-02-01
JPS57176960A (en) 1982-10-30
DE3278854D1 (en) 1988-09-08

Similar Documents

Publication Publication Date Title
DE3107100A1 (de) Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
EP0055208B1 (de) Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CH636354A5 (de) Neue prostaglandin-i(2)-derivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
DE3306123A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CH625797A5 (https=)
DE3226550A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CH636082A5 (de) Prostanderivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
EP0105288B1 (de) Carbacycline, herstellung und verwendung
DE2719901A1 (de) Pge- und 11-deoxy-pge-verbindungen mit einer methylengruppe am c-9
DE2907118A1 (de) Neue prostacyclin-derivate und verfahren zu ihrer herstellung
EP0086404B1 (de) Neue Carbacycline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE3104044A1 (de) Neue prostacyclin-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0094951B1 (de) Neue prostacycline und verfahren zu ihrer herstellung
DE2606051A1 (de) 2,2-difluor-prostaglandin-e, -f tief alpha, -f tief beta, -a und -b-analoga und verfahren zu deren herstellung
DE3035454A1 (de) 7-oxoprostacyclinderivate und verfahren zu ihrer herstellung
DE2542686A1 (de) 2a,2b-dihomo-15-methyl- und -15- aethyl-pgf-und pge-verbindungen und verfahren zu deren herstellung
DE2830478A1 (de) Prostaglandin-analoge
DE3428266A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
EP0324815A1 (de) Neue 9-substituierte carbacyclinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3209702A1 (de) Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DD233997A5 (de) Verfahren zur herstellung von carbacyclinen
EP0058632B1 (de) (13E)-(8R,11R,12R)-11,15-Dihydroxy-16,19-dimethyl-9-oxo-13,18-prostadiensäuren sowie deren Salze, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE2733282A1 (de) Neue prostaglandin-analoga
EP0163672A1 (de) 20-alkyl-7-oxoprostacyclinderivate und verfahren zu ihrer herstellung.
DD210028B3 (de) Verfahren zur herstellung von carbacyclinderivaten

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8131 Rejection